• Publications
  • Influence
Multiple loci identified in a genome-wide association study of prostate cancer
The findings point to multiple loci with moderate effects associated with susceptibility to prostate cancer that, taken together, in the future may predict high risk in select individuals.
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1)
A three-stage genome-wide association study of breast cancer in 9,770 cases and 10,799 controls in the Cancer Genetic Markers of Susceptibility (CGEMS) initiative confirmed associations with loci on chromosomes 2q35, 5p12, 5q11.2, 8q24, 10q26 and 16q12.1.
Current issues in the management of endometrial cancer.
The diagnosis and management of EC is summarized and the role of surgical staging in reducing both overuse and underuse of radiation therapy is discussed, along with current controversies and upcoming investigations pertaining to EC staging and adjuvant treatment.
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress
An in-depth review of the literature is provided to highlight the importance of CA125 as a prognostic and diagnostic marker for ovarian cancer and the increasing body of literature describing the biological role of MUC16 in the progression and metastasis of ovarian tumors.
Identification of a new prostate cancer susceptibility locus on chromosome 8q24
We report a genome-wide association study in 10,286 cases and 9,135 controls of European ancestry in the Cancer Genetic Markers of Susceptibility (CGEMS) initiative. We identify a new association
Genome-wide association studies in cancer--current and future directions.
GWAS are an important discovery tool that require extensive follow-up to map each region, investigate the biological mechanism underpinning the association and eventually test the optimal markers for assessing risk for a disease or its outcome, such as in pharmacogenomics.
BAD Phosphorylation Determines Ovarian Cancer Chemosensitivity and Patient Survival
The BAD apoptosis pathway influences OVCA chemosensitivity and overall survival, likely via modulation of BAD phosphorylation.
The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin.
The BAD pathway represents an appealing therapeutic target to increase EC cell sensitivity to cisplatin, likely via modulation of the phosphorylation status of the BAD protein.
Uterine sarcoma: a clinicopathological study of 93 cases.
Although surgery was the most frequent treatment, adjuvant therapies have been analyzed and discussed and stage I uterine sarcoma has a better prognosis than other stages.
Primary squamous cell cancer of the vulva: radical versus modified radical vulvar surgery.
Modified radical vulvar surgery is associated with decreased complications and 5-year overall and disease-free survival and recurrence rates similar to those of radical vul var surgery.